CN111700870A - Production method of novel NMN + SFE compound medicament - Google Patents
Production method of novel NMN + SFE compound medicament Download PDFInfo
- Publication number
- CN111700870A CN111700870A CN202010759581.2A CN202010759581A CN111700870A CN 111700870 A CN111700870 A CN 111700870A CN 202010759581 A CN202010759581 A CN 202010759581A CN 111700870 A CN111700870 A CN 111700870A
- Authority
- CN
- China
- Prior art keywords
- sfe
- raw material
- nmn
- powder
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a production method of a novel NMN + SFE compound medicament, which comprises the following operation steps: step S1, preparing raw materials; step S2, quantitative weighing; step S3, homogenizing and mixing; step S4, granulating and finishing; step S5, tabletting and forming; step S6, coating the finished product; step S7, quality inspection; step S8, packaging and leaving factory, the novel NMN and SFE compound medicament preparation process comprises the steps of selecting an NMN raw material, an SFE raw material, glucose powder, taxus chinensis powder, cordyceps sinensis powder, gynostemma pentaphylla powder, human placenta powder, protein oligopeptide and soybean lecithin, drying, crushing and sieving the powder raw material components respectively to obtain uniform raw material granules, and carrying out a series of steps of quantitative weighing, homogeneous mixing, granulation, tabletting and forming, finished product coating, quality inspection, packaging and leaving factory and the like to obtain the NMN and SFE compound medicament granules.
Description
Technical Field
The invention relates to the technical field of NMN and SFE compound medicaments, in particular to a production method of a novel NMN + SFE compound medicament.
Background
Nicotinamide adenine dinucleotide (NMN) is a substance contained in a human body, is rich in various vegetables and fruits such as broccoli, avocado and the like, is a precursor substance of NAD +, and is mainly realized by NAD +. NAD < + >, also called coenzyme I, participates in regulating and controlling various physiological processes in organisms, such as energy supply, sugar metabolism regulation, neurocognition and the like, most attention is paid and most known to be important in delaying senescence and maintaining the vitality of organism cells by supplementing NAD < + >, Sulforaphane (SFE) is one of a plurality of isothiocyanates and is abundant in cruciferous plants. Experiments prove that the SFE is one of natural active substances with the most excellent anticancer effect, and the broad-spectrum anticancer property of the SFE aiming at various tumors such as liver cancer, lung cancer, gastric cancer and the like is concerned by more and more researchers. In addition to the obvious inhibition of the growth and the metastasis of various tumors, the SFE also shows good anti-oxidation and anti-inflammatory properties and has a good repairing effect on cell aging and damage caused by various factors inside and outside the body, however, in the prior art, a mature preparation process of a compound medicament of NMN and SFE is not available, and in view of the above problems, the present invention is developed through intensive research.
Disclosure of Invention
The invention aims to solve the problems, designs a novel NMN + SFE compound medicament production method and solves the problems in the background technology.
The technical scheme of the invention for realizing the aim is as follows: a production method of a novel NMN + SFE compound medicament comprises the following operation steps: step S1, preparing raw materials; step S2, quantitative weighing; step S3, homogenizing and mixing; step S4, granulating and finishing; step S5, tabletting and forming; step S6, coating the finished product; step S7, quality inspection; step S8, packaging and leaving factory;
the step S1: selecting an NMN raw material, an SFE raw material, a glucose powder, a taxus chinensis powder, a cordyceps sinensis powder, a gynostemma pentaphylla powder, a human placenta powder, a protein oligopeptide and soybean lecithin, and respectively drying, crushing and sieving the powder raw material components to obtain uniform raw material granules;
the step S2: weighing the various raw material particles prepared in the step 1 according to the mixture ratio, wherein the raw material particles comprise the following specific components in parts by mass: 5-10% of NMN, 5-15% of SFE, 5-8% of glucose particles, 5-8% of taxus chinensis particles, 10-12% of cordyceps sinensis particles, 8-12% of gynostemma pentaphylla particles, 5-7% of human placenta particles, 30-45% of protein oligopeptide and 20-35% of soybean lecithin;
the step S3: putting the raw material particles weighed in the step S2 into a mixer, and mixing and uniformly stirring to obtain a composition;
the step S4: feeding the composition obtained in step S3 to a granulating machine, and performing granulation and size stabilization;
the step S5: tabletting the whole composition in a tabletting machine to obtain a flaky composite medicament;
the step S6: coating the flaky compound medicament prepared in the step S5 to prepare NMN and SFE compound medicinal granules;
the step S7: performing quality inspection on the NMN and SFE compound medicine granules prepared in the step S6;
the step S8: and quantitatively filling, packaging and leaving the factory for the qualified compound medicine granules.
And in the step S1, various raw materials are crushed and then screened by a screen mesh number not less than 1250 meshes, and the granularity of raw material particles is not more than 10 microns.
The NMN starting material may be prepared by an organic catalytic process.
The SFE feedstock can be purified by extraction by supercritical methods.
And in the step S3, the material mixing speed is 200 revolutions per minute, each stirring time is 15 minutes, and the mixture is kept still for 5 minutes.
The output of the granulator in the step S4 is 20-30kg/h, and the swing amplitude is 360 degrees.
The output of the wafer pressing machine in the step S5 is 3500-4000 wafers per hour, and the rotating speed is 1400 revolutions per minute.
In the step S4, a 75% ethanol solution was added as a binder during granulation.
In the step S6, the coating of the compound medicament is sugar coating, and edible pigment may be added to the sugar coating syrup.
The raw material in the step S2 can also comprise 0.1-10% of fucoidin and 0.05-10% of hydrolyzed protein according to the mass portion.
The novel NMN and SFE compound medicament prepared by the technical scheme of the invention selects NMN raw material, SFE raw material, glucose powder, yew powder, aweto powder, gynostemma pentaphylla powder, human placenta powder, protein oligopeptide and soybean lecithin, respectively dries, crushes and screens the powder raw material components to obtain uniform raw material particles, and prepares NMN and SFE compound medicament particles, nicotinamide adenine dinucleotide (NMN) through a series of steps of quantitative weighing, homogeneous mixing, granulation and finishing, tabletting and forming, finished product coating, quality inspection, packaging and delivery and the like, wherein the NMN can maintain NAD + in a body at a higher activity level after entering the human body, further activates Sirtuin protein family members, realizes epigenetic regulation of downstream transcription factors and regulatory proteins, and finally achieves the effect of prolonging the life cycle of cells, sulforaphene (SFE) can obviously inhibit the growth and metastasis of various tumors, and the SFE also has good antioxidant and anti-inflammatory properties and has a good repairing effect on cell aging injury caused by various factors inside and outside a body. .
Detailed Description
The invention is described in detail below, and a method for producing a novel NMN + SFE compound medicament comprises the following operation steps: step S1, preparing raw materials; step S2, quantitative weighing; step S3, homogenizing and mixing; step S4, granulating and finishing; step S5, tabletting and forming; step S6, coating the finished product; step S7, quality inspection; step S8, packaging and leaving factory; the step S1: selecting an NMN raw material, an SFE raw material, a glucose powder, a taxus chinensis powder, a cordyceps sinensis powder, a gynostemma pentaphylla powder, a human placenta powder, a protein oligopeptide and soybean lecithin, and respectively drying, crushing and sieving the powder raw material components to obtain uniform raw material granules; the step S2: weighing the various raw material particles prepared in the step 1 according to the mixture ratio, wherein the raw material particles comprise the following specific components in parts by mass: 5-10% of NMN, 5-15% of SFE, 5-8% of glucose particles, 5-8% of taxus chinensis particles, 10-12% of cordyceps sinensis particles, 8-12% of gynostemma pentaphylla particles, 5-7% of human placenta particles, 30-45% of protein oligopeptide and 20-35% of soybean lecithin; the step S3: putting the raw material particles weighed in the step S2 into a mixer, and mixing and uniformly stirring to obtain a composition; the step S4: feeding the composition obtained in step S3 to a granulating machine, and performing granulation and size stabilization; the step S5: tabletting the whole composition in a tabletting machine to obtain a flaky composite medicament; the step S6: coating the flaky compound medicament prepared in the step S5 to prepare NMN and SFE compound medicinal granules; the step S7: performing quality inspection on the NMN and SFE compound medicine granules prepared in the step S6; the step S8: quantitatively filling, packaging and leaving the factory for the qualified compound medicine granules; in the step S1, various raw materials are crushed and then screened by a screen mesh number not less than 1250 meshes, and the granularity of raw material particles is not more than 10 microns; the NMN starting material may be prepared by an organic catalytic process; the SFE raw material can be extracted and purified by a supercritical method; the mixing speed in the step S3 is 200 revolutions per minute, and the mixture is kept stand for 5 minutes every 15 minutes of stirring; the output of the granulator in the step S4 is 20-30kg/h, and the swing amplitude is 360 degrees; the output of the wafer pressing machine in the step S5 is 3500-4000 wafers per hour, and the rotating speed is 1400 revolutions per minute; adding 75% ethanol solution as a binder during granulation in the step S4; in the step S6, the coating of the compound medicament is sugar coating, and edible pigment may be added to the sugar coating syrup; the raw material in the step S2 can also comprise 0.1-10% of fucoidin and 0.05-10% of hydrolyzed protein according to the mass portion. .
The implementation scheme is characterized by comprising the following operation steps: step S1, preparing raw materials; step S2, quantitative weighing; step S3, homogenizing and mixing; step S4, granulating and finishing; step S5, tabletting and forming; step S6, coating the finished product; step S7, quality inspection; step S8, packaging and leaving factory; step S1: selecting an NMN raw material, an SFE raw material, a glucose powder, a taxus chinensis powder, a cordyceps sinensis powder, a gynostemma pentaphylla powder, a human placenta powder, a protein oligopeptide and soybean lecithin, and respectively drying, crushing and sieving the powdery raw material components to obtain uniform raw material granules; step S2: weighing the various raw material particles prepared in the step 1 respectively according to a ratio, wherein the raw material particles comprise the following specific components in parts by mass: 5-10% of NMN, 5-15% of SFE, 5-8% of glucose particles, 5-8% of taxus chinensis particles, 10-12% of cordyceps sinensis particles, 8-12% of gynostemma pentaphylla particles, 5-7% of human placenta particles, 30-45% of protein oligopeptide and 20-35% of soybean lecithin; step S3: putting the raw material particles weighed in the step S2 into a mixer, and mixing and uniformly stirring to obtain a composition; step S4: putting the composition prepared in the step S3 into a granulator, and granulating and finishing; step S5: tabletting the whole composition in a tabletting machine to obtain a flaky composite medicament; step S6: coating the flaky compound medicament prepared in the step S5 to prepare NMN and SFE compound medicinal granules; step S7: performing quality inspection on the NMN and SFE compound medicine granules prepared in the step S6; step S8: quantitatively filling, packaging and leaving the factory for the qualified compound medicine granules; the novel NMN and SFE compound medicament preparation process comprises the steps of selecting NMN raw materials, SFE raw materials, glucose powder, taxus chinensis powder, cordyceps sinensis powder, gynostemma pentaphylla powder, human placenta powder, protein oligopeptide and soybean lecithin, drying, crushing and sieving the powder raw materials respectively to obtain uniform raw material granules, carrying out a series of steps of quantitative weighing, homogeneous mixing, granulation and finishing, tabletting and forming, finished product coating, quality inspection, packaging and the like to obtain the NMN and SFE compound medicament granules, nicotinamide adenine dinucleotide (NMN), wherein after the NMN enters a human body, NAD < + > in the human body can be maintained at a higher activity level, Sirtuin protein family members are further activated, epigenetic regulation and control of downstream transcription factors and regulatory proteins are realized, and the effect of prolonging the cell life cycle is finally achieved, and Sulforaphene (Sulfoapheene, SFE), besides the growth and metastasis of various tumors can be obviously inhibited, the SFE also shows good antioxidant and anti-inflammatory properties, and has a good repairing effect on cell aging injury caused by various factors inside and outside the body.
The following mainly introduces the working principle and process:
example (b): a method for producing novel NMN + SFE compound medicament comprises the following steps:
step S1, raw material preparation: selecting an NMN raw material, an SFE raw material, a glucose powder, a taxus chinensis powder, a cordyceps sinensis powder, a gynostemma pentaphylla powder, a human placenta powder, a protein oligopeptide and soybean lecithin, and respectively drying, crushing and sieving the powdery raw material components to obtain uniform raw material granules; in the step S1, various raw materials are crushed and then screened by a screen mesh number not less than 1250 meshes, and the granularity of raw material particles is not more than 10 microns; NMN raw material can be prepared by an organic catalytic method, and SFE raw material can be extracted and purified by a supercritical method;
step S2, quantitative weighing: weighing the various raw material particles prepared in the step 1 respectively according to a ratio, wherein the raw material particles comprise the following specific components in parts by mass: 5-10% of NMN, 5-15% of SFE, 5-8% of glucose particles, 5-8% of taxus chinensis particles, 10-12% of cordyceps sinensis particles, 8-12% of gynostemma pentaphylla particles, 5-7% of human placenta particles, 30-45% of protein oligopeptide and 20-35% of soybean lecithin; the raw material can also comprise 0.1 to 10 percent of fucoidin and 0.05 to 10 percent of hydrolyzed protein according to the mass portion;
step S3, homogenizing and mixing: putting the raw material particles weighed in the step S2 into a mixer, and mixing and uniformly stirring to obtain a composition;
step S4, granulation and finishing: putting the composition prepared in the step S3 into a granulator, adding 75% ethanol solution as a bonding agent during granulation, and performing granulation and granule finishing, wherein the mixing speed is 200 revolutions per minute, the stirring is carried out for 15 minutes every time, the standing is carried out for 5 minutes, the yield is 20-30kg/h, and the swinging amplitude is 360 degrees;
step S5, tabletting and forming: tabletting the whole composition in a tabletting machine to obtain a flaky composite medicament, wherein the yield is 3500 and 4000 tablets per hour, and the rotating speed is 1400 revolutions per minute;
step S6, coating of finished products: coating the tablet-shaped compound medicament prepared in the step S5 to prepare NMN and SFE compound medicinal granules, wherein the coating of the compound medicament adopts sugar coating, and edible pigment can be added into sugar coating raw material syrup;
step S7, quality inspection: performing quality inspection on the NMN and SFE compound medicine granules prepared in the step S6;
step S8, packaging and leaving factory: and (4) quantitatively filling, packaging and leaving the factory for the qualified compound medicine granules, and finishing the preparation work of the novel NMN and SFE compound medicine granules.
It is important to point out that nicotinamide adenine dinucleotide (NMN) is a substance contained in the human body, is abundant in various vegetables and fruits such as broccoli, avocado and the like, is a precursor substance of NAD +, and the function of the nicotinamide adenine dinucleotide is mainly realized through the NAD +. NAD + is also called coenzyme I, participates in regulating and controlling various physiological processes in the body, such as energy supply, sugar metabolism regulation, neurocognition and the like, and most attention is paid and most people know that the NAD + is supplemented to play an important role in delaying senility and maintaining the vitality of cells of the body. Research shows that compared with Nicotinic Acid (NA), Nicotinamide (NAM) and Nicotinamide Ribose (NR) which are precursors of NAD +, NMN is the most safe and efficient means for supplementing NAD + at present and the preparation process is simpler. After NMN is ingested, NAD + in the organism is maintained at a higher activity level, the Sirtuin protein family members are further activated, the epigenetic regulation of downstream transcription factors and regulatory proteins is realized, and finally the effect of prolonging the life cycle of cells is achieved. The symptoms caused by NAD + deficiency vary from person to person, as they are widely distributed in different tissues inside the body, and the changes caused by the supplementation of NAD + to normal levels are also different. For example, in the case of patients with cardiovascular chronic diseases, the increase of the content of NAD + can effectively improve arteriosclerosis and reduce the incidence probability of myocardial inflammation, while in the case of patients with Parkinson, NAD + can repair mitochondrial function and generate enough ATP required by human bodies, and can improve memory and improve sleep quality. As NAD + can improve the functions of human bodies in a multi-angle and omnibearing manner, more and more researches on the prevention and treatment of basic diseases are published on participating in adjuvant therapy of certain precancerous lesions, and the NAD + is widely concerned by researchers as NMN which is the best choice for supplementing NAD +.
Sulforaphane (SFE), one of many isothiocyanates, is abundant in cruciferous plants. Experiments prove that the SFE is one of natural active substances with the most excellent anticancer effect, and the broad-spectrum anticancer property of the SFE aiming at various tumors such as liver cancer, lung cancer, gastric cancer and the like is concerned by more and more researchers. Besides the obvious inhibition of the growth and the metastasis of various tumors, the SFE also shows good antioxidant and anti-inflammatory properties and has better repairing effect on cell aging damage caused by various factors inside and outside the body. Reactive Oxygen Species (ROS) generated by oxidative stress can directly or indirectly destroy the active structure of biomacromolecules in cells, damage the physiological functions of various substances including nucleic acid and protein, and serve as the pathophysiological basis for the occurrence of a plurality of diseases such as human Alzheimer's disease, diabetes, heart failure and the like. The human body forms a complex response system for resisting ROS, when strong electrophilic reagents are present or ROS continuously stimulate, a series of protective proteins can sequentially induce expression, and the nuclear factor E2 related factor 2(NRF2) is a key factor. NRF2 is expressed in cells of various tissues such as heart, liver, spleen and kidney of human body, under normal physiological condition, it is anchored in cytoplasm by Keap1 and is ubiquinated under the action of E3 ubiquitin ligase, and finally is degraded by proteasome, but when cells are attacked by a large amount of ROS, NRF2 translocates into cell nucleus to combine with an antioxidant reaction element, and genes of II phase detoxification enzyme and antioxidant enzyme are transcriptionally activated. Studies show that SFE is a high-efficiency activator of NRF2, can promote the dissociation of NRF2 and Keap1, enables NRF2 to exert transcription factor activity, improves oxidative stress state, and realizes the maintenance of cell activity and homeostasis. Target genes downstream of NRF2 include Heme Oxygenase 1 (HO-1), superoxide dismutase (SOD), Catalase (Catalase, CAT) and other antioxidases, which play important roles in various tissues and organs of human body such as central nervous system, cardiovascular system, digestive system and the like, so NRF2 becomes a potential target for atherosclerosis, diabetes, hypertension and other diseases, and SFE is also considered as one of the most promising clinical treatment means.
NMN and SFE have the characteristics of maintaining homeostasis, repairing cell damage, maintaining body vitality and delaying aging, and research on improving NMN level to improve ischemic brain damage discovers that NMN improves the biological energy metabolism of tissues mainly by activating NRF2 and HO-1 downstream of the NRF2 to prevent nerve cell apoptosis caused by cerebral ischemia and promote nerve regeneration of damaged tissues. Both NMN and SFE share similarities, both in clinical changes after ingestion and in regulatory mechanisms behind related traits, suggesting the possibility of enhancing body functions to a greater extent, maintaining the physiological activity of each large tissue, and delaying aging by combining both substances. NMN is a substance existing in a human body, SFE belongs to a natural active product, and according to the previous research, the NMN and the SFE have no obvious antagonism and do not cause harm to the human body, thereby further illustrating the feasibility of combined medication.
The technical solutions described above only represent the preferred technical solutions of the present invention, and some possible modifications to some parts of the technical solutions by those skilled in the art all represent the principles of the present invention, and fall within the protection scope of the present invention.
Claims (10)
1. A production method of a novel NMN + SFE compound medicament is characterized by comprising the following operation steps: step S1, preparing raw materials; step S2, quantitative weighing; step S3, homogenizing and mixing; step S4, granulating and finishing; step S5, tabletting and forming; step S6, coating the finished product; step S7, quality inspection; step S8, packaging and leaving factory;
the step S1: selecting an NMN raw material, an SFE raw material, a glucose powder, a taxus chinensis powder, a cordyceps sinensis powder, a gynostemma pentaphylla powder, a human placenta powder, a protein oligopeptide and soybean lecithin, and respectively drying, crushing and sieving the powder raw material components to obtain uniform raw material granules;
the step S2: weighing the various raw material particles prepared in the step 1 according to the mixture ratio, wherein the raw material particles comprise the following specific components in parts by mass: 5-10% of NMN, 5-15% of SFE, 5-8% of glucose particles, 5-8% of taxus chinensis particles, 10-12% of cordyceps sinensis particles, 8-12% of gynostemma pentaphylla particles, 5-7% of human placenta particles, 30-45% of protein oligopeptide and 20-35% of soybean lecithin;
the step S3: putting the raw material particles weighed in the step S2 into a mixer, and mixing and uniformly stirring to obtain a composition;
the step S4: feeding the composition obtained in step S3 to a granulating machine, and performing granulation and size stabilization;
the step S5: tabletting the whole composition in a tabletting machine to obtain a flaky composite medicament;
the step S6: coating the flaky compound medicament prepared in the step S5 to prepare NMN and SFE compound medicinal granules;
the step S7: performing quality inspection on the NMN and SFE compound medicine granules prepared in the step S6;
the step S8: and quantitatively filling, packaging and leaving the factory for the qualified compound medicine granules.
2. The method as claimed in claim 1, wherein the raw materials are pulverized and sieved to have a mesh size of 1250 meshes or more, and the particle size of the raw material particles is not greater than 10 μm in step S1.
3. The method as claimed in claim 1, wherein the NMN starting material is prepared by organic catalysis.
4. The method as claimed in claim 1, wherein the SFE material is purified by supercritical extraction.
5. The method as claimed in claim 1, wherein the mixing speed in step S3 is 200 rpm, 15 minutes per stirring, and 5 minutes per standing.
6. The method as claimed in claim 1, wherein the granulator in step S4 has a throughput of 20-30kg/h and a swing amplitude of 360 °.
7. The method as claimed in claim 1, wherein the throughput of the tabletting machine in step S5 is 3500-4000 tablets per hour, and the rotation speed is 1400 rpm.
8. The method as claimed in claim 1, wherein 75% ethanol solution is added as a binder during the granulation in step S4.
9. The method as claimed in claim 1, wherein the coating of the combination drug is sugar coating, and edible pigment can be added into the sugar coating syrup in step S6.
10. The method as claimed in claim 1, wherein the raw material of step S2 further comprises fucoidan 0.1-10 wt% and hydrolyzed protein 0.05-10 wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010759581.2A CN111700870A (en) | 2020-07-31 | 2020-07-31 | Production method of novel NMN + SFE compound medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010759581.2A CN111700870A (en) | 2020-07-31 | 2020-07-31 | Production method of novel NMN + SFE compound medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111700870A true CN111700870A (en) | 2020-09-25 |
Family
ID=72546920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010759581.2A Pending CN111700870A (en) | 2020-07-31 | 2020-07-31 | Production method of novel NMN + SFE compound medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111700870A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024037484A1 (en) * | 2022-08-15 | 2024-02-22 | 江苏蓝果临床营养科技有限公司 | Nicotinamide mononucleotide composite and preparation method therefor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109045158A (en) * | 2018-10-12 | 2018-12-21 | 泓博元生命科技（深圳）有限公司 | A kind of composition and preparation method and application containing NMN |
-
2020
- 2020-07-31 CN CN202010759581.2A patent/CN111700870A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109045158A (en) * | 2018-10-12 | 2018-12-21 | 泓博元生命科技（深圳）有限公司 | A kind of composition and preparation method and application containing NMN |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024037484A1 (en) * | 2022-08-15 | 2024-02-22 | 江苏蓝果临床营养科技有限公司 | Nicotinamide mononucleotide composite and preparation method therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110338412A (en) | The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application | |
| CN111700870A (en) | Production method of novel NMN + SFE compound medicament | |
| CN115463147A (en) | Composition with functions of improving immunity and resisting aging and preparation process thereof | |
| CN102430110B (en) | CAlprostadil composite medicament of compound fermented cordyceps sinensis powder and alprostadil composite drug | |
| CN101095805A (en) | Medicine made by onion and aloe and method for preparing the same | |
| CN113826891A (en) | Composition containing compound vitamin and tabletting preparation method and application thereof | |
| CN102488721A (en) | Preparation method for ginkgo leaf extracts and preparation of ginkgo leaf extracts | |
| CN101703540A (en) | Celeryseed extract pellets and preparation method thereof | |
| CN104147012B (en) | A kind of oral disintegrated preparation containing ftorafur, Gimeracil and oteracil potassium | |
| CN101953857A (en) | Compound fermented cordyceps sinensis bacterium powder (paecilomyces hepiali Cs-4 bacterium powder) composite medicine | |
| CN115124420A (en) | Rhein and matrine eutectic crystal hydrate, preparation method, composition and application thereof | |
| CN101368176B (en) | Complex phospho-esterase, extraction method and complex phospho-esterase capsule | |
| CN104098622B (en) | Beta-arbutin crystal IV substance, preparation method, composition and application thereof | |
| CN104098621B (en) | Beta-arbutin crystal III substance, preparation method, composition and application thereof | |
| CN110407876B (en) | Febuxostat and phosphocreatine derivative, preparation method thereof and application thereof in preparation of anti-myocardial cell injury drugs | |
| CN101438795B (en) | SOD red date lozenge and preparation method thereof | |
| CN102786521B (en) | Risperidone brilliant type III material and preparation method and apply in medicine and healthcare products | |
| CN101773529B (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof | |
| CN102727863B (en) | Combined drug of compound fermented Cordyceps sinensis powder and ginsenoside Rg1 | |
| CN105461658A (en) | Dimolecular 3-piperidyl-propiophenone hydrochloride I crystal form substance, and preparation method, composition and use thereof | |
| CN102429930B (en) | Compound fermented cordyceps fungus powder and baicalin combined drug, | |
| CN102429931B (en) | Compound fermented cordyceps fungus powder salvianic acid combined drug | |
| CN102429929B (en) | Compound fermented cordyceps fungus powder and taurine combined drug | |
| CN115785050A (en) | Method for extracting and preparing anthocyanin from stem and leaf of black leaf rice | |
| CN114652740A (en) | Pharmaceutical composition of leonurine, polygonatum polysaccharide and deoxynojirimycin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200925 |
|
| RJ01 | Rejection of invention patent application after publication |